MedTrace Logo

Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia

NCT01213524 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2020-10-19

Study results available
· View outcomes & findings →

Summary

The objective of this study is to investigate the relative contributions of nicotine replacement and sensorimotor replacement (i.e., smoking denicotinized cigarettes) on abstinence-induced smoking urges, withdrawal-related negative affect, psychiatric symptoms, cognitive task performance and 90-min ad libitum usual-brand smoking behavior in smokers with schizophrenia and non-psychiatric smokers.

Conditions

Interventions

BEHAVIORAL

sensorimotor replacement

denicotinized cigarettes

DRUG

42 mg transdermal nicotine replacement

2 21-mg nicotine patches

DRUG

Placebo transdermal nicotine

2 placebo patches matched to 21-mg nicotine patches

OTHER

usual brand smoking

participant smokes usual brand of cigarette

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Brown University

    lead OTHER

Principal Investigators

  • Jennifer Tidey, Ph.D. · Brown University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01213524 on ClinicalTrials.gov